Observations placeholder
Epilepsy caused by tumours
Identifier
005718
Type of Spiritual Experience
Background
A description of the experience
Lecture: profile of risks and benefits of new antiepileptic drugs in brain tumor-related epilepsy - Maschio M, Dinapoli L.; Center for Tumor-related Epilepsy, Neurology Unit, Department of Neuroscience and Cervical-facial Pathology, National Institute for Cancer "Regina Elena", Via Elio Chianesi 53, 00144, Rome, Italy.
In patients with brain tumour, seizures are the onset symptom in 20-40% of the patients, while a further 20-45% of the patients will present them during the course of the disease. These data are important when considering the choice of antiepileptic drugs for this particular patient population, because brain tumor-related epilepsy (BTRE) is often drug resistant, has a strong impact on the quality of life and weighs heavily on public health expenditures.
In brain tumour patients, the presence of epilepsy is considered as the most important risk factor for long-term disability. For this reason, the problem of the proper administration of medications and their potential side effects is of great importance, because good seizure control can significantly improve the patient's psychological and relational sphere.